From Design to Implementation of SARS-CoV-2 Diagnostic Testing

Sponsored by: Scientific Affairs, Molecular Diagnostics at Abbott

Speakers

Dr. Gavin Cloherty

Head of Infectious Disease Research, Abbott
BIOGRAPHY
Dr. Frederick (Rick) Nolte, PhD

Professor & Vice Chair, Laboratory Medicine, and Medical Director of Clinical Laboratories & Molecular Pathology, Medical University of South Carolina
BIOGRAPHY
Dr. James Kirby, MD

Associate Professor, Pathology, Harvard Medical School and Director of the Clinical Microbiology Laboratory, Beth Israel Deaconess Medical
BIOGRAPHY

Event Date & Time

DATE: July 8, 2020

TIME: 10:00 am PDT

Abstract

Since it was first detected in Wuhan, China, in 2019, the novel coronavirus SARS-CoV-2 and the disease it causes, COVID-19, have spread rapidly across the globe. Slowing the spread of the disease relies on social distancing measures as well as widespread and rapid diagnostic testing. This webinar will discuss design and development of the SARS CoV-2 diagnostic assay as well as review different strategies on the implementation of SARS-CoV-2 molecular testing under FDA Emergency Use Authorization only (EUA) in a US Integrated Hospital Delivery Network (IDN).

Learning Objectives:

Understand Important assay features to consider during design and development of SARS CoV-2 assay
Review challenges and successes during implementation and scale up of SARS-CoV-2 Testing
Evaluate different applications of SARS-CoV-2 PCR results to understand disease status and progression

Webinars will be available for unlimited on-demand viewing after live event.